AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week.
At a site that employs more than 2,000 already, the new building will house more than 300 employees in oncology, neuroscience and immunology. It adds to the approximately €250 million ($269 million) AbbVie has invested into Germany since 2020.
Martin GastensMartin Gastens, vice president of biologics drug product development and managing director for R&D at AbbVie Germany, wrote in a statement that the construction of what the company is calling the “LUnA” research building “is much more than a €150 million investment in cutting-edge infrastructure.”
“We are creating attractive working conditions for our top scientists and attracting new talent so that we can conduct cutting-edge research at our site in the long term,” Gastens wrote.
The investment is the latest in manufacturing and R&D over the last several years as megablockbuster Humira’s sales dip following biosimilars’ market entry.
In January, AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility, adding more than 100 jobs and additional biologics manufacturing capacity, with operations expected to start in 2026. In 2022, the company also opened a new research facility in San Francisco.
AbbVie has also made investments into its pipeline and portfolio, including the acquisitions of ADC biotech ImmunoGen in a deal worth $10.1 billion, and CNS company Cerevel for $8.7 billion.